Table 1 (abstract LB1). Comparison of clinical and laboratory parameters and treatment modalities based on mortality
From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
Parameter | Survivors (n=27) | Non-survivors (n=4) | p-value |
|---|---|---|---|
Age, Age in months, median (IQR) | 96 (60,120) | 130.5 (72,161) | 0.26 |
Shock, n (%) | 14 (51.85) | 4 (100) | 0.12 |
Gastrointestinal symptoms,n (%) | 18 (66.66) | 4 (100) | 0.29 |
Respiratory symptoms, n(%) | 17 (62.96) | 4 (100) | 0.29 |
Skin rash, n(%) | 17 (62.96) | 0 | 0.032 |
Pre-existing comorbidity, n(%) | 8/27 | 4/4 | 0.189 |
Laboratory parameters | |||
 Total Leucocyte Count, median (IQR) | 13240 (7700,20000) | 19685 (12450,27285) | 0.51 |
 Platelet count (x105/mm3), median (IQR) | 2.05 (1.5,3.46) | 0.46 (0.17, 2.56) | 0.098 |
 Serum IL-6 (5.00-15.0 pg/mL), median (IQR) | 41.84 (12.9,194) (n=19) | 55.06 (27.06,328.76) (n=4) | 0.21 |
 Serum ferritin (12- 300 ng/ml), median (IQR) | 309.5 (140,720.08) | 1061 (581,2750) | 0.045 |
 NT-ProBNP (pg/mL), median (IQR) (<125pg/ml) | 248.63 (24.66,3189.7) (n=13) | 6078.29 (1500.04,10656.5) (n=2) | 1.46 |
 D-dimer (ng/ml), median (IQR) (0.00-255.00ng/ml) | 1050 (741.05,5056) (n=17) | 4285 (385,14035) (n=4) | 0.16 |
Immunomodulation therapy | |||
 Supportive care only (n=5) | 5 | 0 | 0.137 |
 Only IVIG (n=6) | 5 | 1 | |
 Only steroids (n=5) | 4 | 1 | |
 Steroid plus Tocilizumab (n=1) | 0 | 1 | |
 IVIG plus steroids (n=14) | 13 | 1 | |